Safety and Tolerability of MEDI3506 in Healthy Participants, in Participants With COPD and Healthy Japanese Participants

Exclusion Criteria

• •1. Concurrent enrollment in another clinical study involving a study treatment.
• •2. Received administration of study drug or participated in a device trial within 3 months, prior to screening (Visit 1).
• •3. Participant is a participating investigator, sub-investigator, study coordinator or employee of the participating site, or is a first-degree relative of the aforementioned.
• •4. Any active medical or psychiatric condition or other reason which, in the opinion of the investigator or medical monitor, may compromise the safety of the participant in the study or interfere with evaluation of the investigational product or reduce the participant's ability to participate in the study.
• •5. Any clinically relevant abnormal findings on physical examination of the cardiovascular system including electrocardiogram (ECG) and vital signs at screening or randomization.
• •6. Abnormal vital signs, after 10 minutes supine rest.
• •1. Concurrent enrolment in another clinical study involving investigational treatment.
• •2. Received administration of study drug or participated in a device trial within 3 months, prior to screening (Visit 1).
• •3. Participant is a participating investigator, sub-investigator, study coordinator, or employee of the participating site, or is a first-degree relative of the aforementioned.
• •4. Any active medical or psychiatric condition or other reason that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of participant's safety or study results. This includes, but is not limited to:
• •* Uncontrolled diabetes
• •* Hypertension during the screening period
• •* Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure
• •* Clinically significant Aortic stenosis
• •* Pulmonary Arterial Hypertension
• •1. Concurrent enrolment in another clinical study involving study treatment.
• •2. Received administration of study drug or participated in a device trial within 3 months, prior to screening (Visit 1).
• •3. Any active medical or psychiatric condition or other reason which, in the opinion of the investigator or medical monitor, may compromise the safety of the participant in the study or interfere with evaluation of the study product or reduce the participant's ability to participate in the study.
• •4. Any clinically relevant abnormal findings on physical examination of the cardiovascular system including ECG and vital signs at screening, and Day 1(pre-dose).
• •5. Any other clinically relevant abnormal findings on physical examination or laboratory testing including hematology, coagulation, clinical chemistry or urinalysis at screening or randomisation.